Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
This happens because your body is adjusting to a higher amount of medication, and symptoms often improve with time
These effects resolve with dose reduction but indicate levels beyond physiological optimization
Moreover, the percentage of participants in clinical trials who stopped the treatment due to AE was 515% with most of the new agents, and this percentage was up to 2030% with some of GLP-1/glucagon RA in phase 2 trials so a considerable proportion of people may not be able to tolerate the new obesity pharmacotherapies or may be unable to titrate them to the higher and most effective doses
Understanding whether your medication needs special handling matters too
